Trevi Therapeutics (TRVI) Shares Outstanding (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Shares Outstanding (Entity) of $128.4 million for Q1 2026, up 28.55% year-over-year from $99.9 million in Q1 2025, and little changed quarter-over-quarter from $128.3 million in Q4 2025.
Trevi Therapeutics (TRVI) Shares Outstanding (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Shares Outstanding (Entity) history runs 9 years deep, the most recent figure standing at $128.4 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 28.55% year-over-year to $128.4 million; the TTM figure through Mar 2026 stood at $128.4 million (up 28.55% YoY), while the FY2025 annual figure was $128.3 million, up 37.08% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $128.4 million, roughly flat from $128.3 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $128.4 million in Q1 2026, with the low at $30.8 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $99.3 million (2023), against an average of $94.5 million.
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Entity) jumped 220.1% in 2023, then dropped 5.48% in 2024.
- Trevi Therapeutics' Shares Outstanding (Entity) stood at $59.9 million in 2022, then surged by 65.21% to $99.0 million in 2023, then slipped by 5.48% to $93.6 million in 2024, then surged by 37.08% to $128.3 million in 2025, then rose by 0.08% to $128.4 million in 2026.
- Business Quant data shows TRVI's Shares Outstanding (Entity) at $128.4 million in Q1 2026, $128.3 million in Q4 2025, and $128.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | 156.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 156.60 Mn |
| Mar 31, 2026 | 145.59 Mn |
| Dec 31, 2025 | 134.75 Mn |
| Sep 30, 2025 | 145.10 Mn |
| Jun 30, 2025 | 130.35 Mn |
| Mar 31, 2025 | 117.61 Mn |
| Dec 31, 2024 | 101.97 Mn |
| Sep 30, 2024 | 101.28 Mn |
| Jun 30, 2024 | 101.04 Mn |
| Mar 31, 2024 | 99.52 Mn |
| Dec 31, 2023 | 99.03 Mn |
| Sep 30, 2023 | 99.33 Mn |
| Jun 30, 2023 | 98.70 Mn |
| Mar 31, 2023 | 98.61 Mn |
| Dec 31, 2022 | 64.54 Mn |
| Sep 30, 2022 | 68.90 Mn |
| Jun 30, 2022 | 59.54 Mn |
| Mar 31, 2022 | 30.81 Mn |
| Dec 31, 2021 | 22.84 Mn |
| Sep 30, 2021 | 21.61 Mn |